Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Industry performance is calculated based on the previous closing price of all industry constituents
Largest Companies in This Industry
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| 503.84 | 539.24 | 38.96% | | | | Buy | |
| 233.59 | 278.61 | 14.59% | | | | Buy | |
| 242.47 | 249.70 | 7.69% | | | | Buy | |
| 307.93 | 358.24 | 4.82% | | | | Buy | |
| 104.68 | 113.94 | 4.51% | | | | Buy | |
| 80.87 | 88.51 | 4.06% | | | | Buy | |
| 35.70 | 40.84 | 3.94% | | | | Hold | |
| 205.03 | 258.34 | 3.34% | | | | Buy | |
| 22.37 | 26.59 | 3.29% | | | | Buy | |
| 167.91 | 182.20 | 2.41% | | | | Strong Buy |
Investing in the Medical Instruments & Supplies Industry
Start Investing in Medical Instruments & Supplies Through These Companies
Top Performing Companies
View MoreName | Last Price | 1Y Target Est. | YTD Return |
|---|---|---|---|
| 31.02 | 30.00 | | |
| 170.73 | 176.40 | | |
| 88.39 | 96.33 | | |
| 503.84 | 539.24 | | |
| 23.40 | 28.90 | |
High Growth Companies
View MoreName | Last Price | Growth Estimate | YTD Return |
|---|---|---|---|
| 33.00 | | | |
| 6.19 | | | |
| 16.93 | | | |
| 31.02 | | | |
| 88.39 | | |
Medical Instruments & Supplies Research
View MoreDiscover the Latest Analyst and Technical Research for This Industry
Analyst Report: Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
RatingPrice TargetXRAY: Lowering target price to $24.00
DENTSPLY SIRONA INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRGEN: Lowering target price to $116.00
REPLIGEN CORP has an Investment Rating of SELL; a target price of $116.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetICUI: Lowering target price to $184.00
ICU MEDICAL INC has an Investment Rating of HOLD; a target price of $184.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target
